Advanced in Ewing Sarcoma

Dr. Nicholas P. Campbell

Oncology
Endeavor Health Medical Group
5140 N California Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Ewing Sarcoma
Endeavor Health Medical Group
5140 N California Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nicholas Campbell is an Oncologist in Chicago, Illinois. Dr. Campbell is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Campbell is currently accepting new patients.

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

ENDEAVOR HEALTH MEDICAL GROUP
5140 N California Ave, Chicago, IL 60625
Other Locations
ENDEAVOR HEALTH MEDICAL GROUP
777 Park W Ave, Highland Park, IL 60035
ENDEAVOR HEALTH MEDICAL GROUP
1300 Oak Ave, Evanston, IL 60201
ENDEAVOR HEALTH MEDICAL GROUP
2739 W Foster Ave, Chicago, IL 60625
ENDEAVOR HEALTH MEDICAL GROUP
757 Park Ave W, Highland Park, IL 60035
ENDEAVOR HEALTH MEDICAL GROUP
2650 Ridge Ave, Evanston, IL 60201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
View 9 Less Clinical Trials

11 Total Publications

Complete Pathologic Response of Squamous Cell Carcinoma Abutting an Internal Mammary Bypass Graft.
Complete Pathologic Response of Squamous Cell Carcinoma Abutting an Internal Mammary Bypass Graft.
Journal: Annals of thoracic surgery short reports
Published: December 19, 2022
Similar Doctors
Distinguished in Ewing Sarcoma
Dr. Marta Batus
Oncology
Distinguished in Ewing Sarcoma
Dr. Marta Batus
Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (7.2 miles away)
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Batus is an Oncologist in Chicago, Illinois. Dr. Batus is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Batus is currently accepting new patients.

Advanced in Ewing Sarcoma
Dr. Bruce E. Brockstein
Oncology
Advanced in Ewing Sarcoma
Dr. Bruce E. Brockstein
Oncology

Endeavor Health Medical Group

2650 Ridge Ave, 
Evanston, IL 
 (6.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Brockstein is an Oncologist in Evanston, Illinois. Dr. Brockstein is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma. Dr. Brockstein is currently accepting new patients.

Ronald Myint
Advanced in Ewing Sarcoma
Dr. Ronald Myint
Hematology | Oncology
Advanced in Ewing Sarcoma
Dr. Ronald Myint
Hematology | Oncology

Affiliated Oncologists, LLC

10604 Southwest Hwy, 
Chicago Ridge, IL 
 (19.7 miles away)
708-634-4644
Languages Spoken:
English
See accepted insurances

Ronald Myint is a Hematologist and an Oncologist in Chicago Ridge, Illinois. Dr. Myint is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Thrombocytopenia, Lung Cancer, and Pulmonary Embolism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Campbell's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile